サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1447058

低分子標的がん治療市場の2030年までの予測： タイプ別、用途別、地域別の世界分析

Small Molecule Targeted Cancer Therapy Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography
出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
低分子標的がん治療市場の2030年までの予測： タイプ別、用途別、地域別の世界分析
出版日: 2024年03月03日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界の低分子標的がん治療市場は2023年に825億米ドルを占め、予測期間中のCAGRは8.7%で成長し、2030年には1,479億米ドルに達すると予測されています。

低分子医薬品は、高分子医薬品よりも細胞内に浸透しやすく、がん細胞の生存に不可欠なタンパク質や酵素の活性を効果的に阻害することができます。

低分子医薬品とは、低分子を用いてがん細胞を標的とし、その増殖を阻害するよう特別に設計された医薬品の開発・商業化を専門とする製薬業界のセグメントを指します。これらの治療法は、がんの増殖、進行、転移に関与する特定の分子を阻害することによって作用し、従来の化学療法と比較して、より精密で標的を絞った治療法を提供します。

FDAによると、セツキシマブのようなモノクローナル抗体の半減期（3.1～7.8日）は、ゲフィチニブのような低分子薬剤の半減期（48時間）よりもはるかに長いです。

がん罹患率の増加

さまざまな人口統計や地域にわたってがんの罹患率が上昇しているため、効果的な治療オプションに対する需要が高まっています。低分子標的治療薬は、がん細胞の分子変化を特異的に標的とすることで、がん細胞の増殖を抑制したり、健康な細胞への害を最小限に抑えて細胞死を誘導したりする、がん治療の有望な手段を提供します。さらに、化学療法のような伝統的な治療法はしばしば衰弱させる副作用を伴うため、より標的を絞った毒性の低い治療法に対する需要が高まっています。

高い開発コスト

特定のがん細胞を標的とした低分子医薬品の開発には、大規模な調査、臨床試験、規制当局の承認が必要であり、これらすべてに多額の費用がかかります。適切な分子標的を同定し、化合物を設計し、有効性を最適化し、安全性を確保するという複雑なプロセスは、多額の財政投資を必要とします。しかし、厳格な規制要件と長い承認スケジュールは、開発コスト全体をさらにエスカレートさせる。資金力に乏しい中小バイオテクノロジー企業や新興企業にとって、こうした高コストは市場参入の大きな障壁となります。

技術の進歩

ハイスループット・スクリーニング、分子モデリング、計算化学などの最先端技術は、がん標的に対する特異性と有効性を高めた低分子の同定と設計を可能にします。分析技術の進歩により、薬剤候補の正確な特性評価が容易になり、薬物動態学的および薬力学的特性が最適化されます。さらに、ナノテクノロジーや標的薬物送達を含むドラッグデリバリーシステムの革新は、腫瘍への浸透を改善し、標的外影響を低減することにより、低分子医薬品の治療指数を高めています。

限られたバイオマーカー

生物学的プロセスや治療に対する反応を示す測定可能な指標であるバイオマーカーは、標的治療に適した患者を特定する上で重要な役割を果たします。ある種のがんや標的療法に特異的なバイオマーカーの入手可能性はしばしば限られています。この限界は、低分子の標的療法が最も有効な患者の正確な選択を妨げ、最適とは言えない治療結果につながり、潜在的に市場の成長を制限します。したがって、バイオマーカーの欠如は、がん標的薬の有効性を制限し、また、これらの治療の対象となる患者数を減少させることにより、市場の成長を妨げます。

COVID-19の影響：

ヘルスケアサービスやリソースの混乱により、がん治療から注目やリソースがそがれ、診断や治療開始の遅れにつながった。新しい低分子標的治療薬の臨床試験は中断や延期に直面し、新薬の開発や承認の妨げとなった。サプライチェーンの混乱や移動の制限は、既存の治療薬の製造や流通にさらに影響を及ぼし、不足と患者への治療アクセスの遅れを引き起こしました。しかし、ヘルスケアシステムと患者に対する財政的な負担も、これらの治療法の購入可能性と利用率に影響を与えました。

予測期間中、チロシンキナーゼ阻害剤セグメントが最大となる見込み

チロシンキナーゼ阻害剤は、そのユニークな作用機序と様々なタイプのがんに対する有効性から、予測期間中に最大となる見込みです。これらの阻害剤は、がん細胞の成長と増殖に関与するシグナル伝達経路で重要な役割を果たす酵素である特定のチロシンキナーゼを標的とするため、チロシンキナーゼ阻害剤セグメントは予測期間中最大のシェアを占めると予想されます。チロシンキナーゼ阻害剤の精密なターゲティングにより、健康な細胞へのダメージが最小限に抑えられるため、従来の化学療法に比べて副作用が少ないです。さらに、有効性が改善され、毒性プロファイルが低減された新規TKIの市場開拓は、さまざまなタイプのがん患者に対する治療の選択肢を広げ、市場の成長をさらに後押ししています。

予測期間中、メラノーマ分野のCAGRが最も高くなると予測される

メラノーマ分野は、予測期間中に大きな成長を遂げると予測されます。皮膚がんの一種であるメラノーマは、世界的に罹患率が大幅に上昇しており、効果的な治療に対する需要を牽引しています。低分子標的療法は、がんの増殖と進行に関与する分子を特異的に標的とすることで、メラノーマとの闘いにおいて精度を高め、従来の治療法と比較して有効性の向上と副作用の軽減をもたらします。さらに、研究の進歩により、メラノーマに関与する特定の遺伝子変異や経路を標的とした新規の低分子薬剤が開発され、患者が利用できる治療の選択肢が広がっています。これらの要素が、このセグメントの成長を促進しています。

最もシェアの高い地域：

がん治療は、個別化医療として認識されているように、患者固有の分子プロファイルに合わせてカスタマイズされるようになってきているため、アジア太平洋地域が予測期間中、市場で最大のシェアを占めると予想されます。がん患者において特定の低分子を標的とすることで、個々の症例の特殊性を考慮した、より個別化された正確な治療計画が可能になるかもしれないです。ゲノム配列決定技術が発展するにつれて、特定のがんに関連する珍しい遺伝子異常やバイオマーカーを見つけることがより簡単になります。さらに、製薬企業は、この領域で利用可能な豊富な遺伝子データにより、特定の遺伝子プロファイルに関連する高度に標的化された薬剤を作成し、治療効果と精度を向上させることができます。

CAGRが最も高い地域：

ヘルスケア提供者ががん治療における標的治療の利点と有効性について知識を深め、患者に推奨する可能性が高まるにつれて、アジア太平洋地域は予測期間を通じて収益性の高い成長を遂げると推定されます。このような認識は、健康な細胞へのダメージを最小限に抑えつつ、がん細胞を特異的に標的とするよう設計された低分子標的療法の採用拡大につながります。さらに、この地域のヘルスケアプロバイダーは、標的療法をサポートする最新の進歩や臨床エビデンスを常に把握しているため、これらの治療に適した患者を特定し、個々のニーズに合わせて治療レジメンを調整する能力が向上しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング（3社まで）
    • 主要企業のSWOT分析（3社まで）
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査ソース
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • 用途分析
  • 新興市場
  • 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界の低分子標的がん治療市場：タイプ別

  • チロシンキナーゼ阻害剤
  • 低分子薬物複合体
  • その他のタイプ

第6章 世界の低分子標的がん治療市場：用途別

  • 乳がん
  • 多発性骨髄腫
  • 黒色腫
  • リンパ腫
  • 前立腺がん
  • その他の用途

第7章 世界の低分子標的がん治療市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東とアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第8章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第9章 企業プロファイル

  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bayer HealthCare AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cytokinetics Inc
  • Genentech
  • GlaxoSmithKline plc
  • Hospira Inc
  • Novartis
図表

List of Tables

  • Table 1 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 4 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 5 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 7 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 8 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 9 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 10 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 11 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 12 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 13 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 14 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 15 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 16 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 17 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 18 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 20 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 21 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 22 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 23 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 24 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 27 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 28 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 29 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 30 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 32 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 33 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 34 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 35 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 36 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 37 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 39 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 40 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 41 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 42 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 44 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 45 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 46 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 47 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 48 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 49 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 52 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 53 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 54 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 55 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 56 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 57 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 58 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 59 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 60 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 63 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 64 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 65 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 66 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 67 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 68 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 69 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 70 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 71 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 72 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
目次
Product Code: SMRC25319

According to Stratistics MRC, the Global Small Molecule Targeted Cancer Therapy Market is accounted for $82.5 billion in 2023 and is expected to reach $147.9 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Small molecule drugs can penetrate cells more easily than larger molecules, allowing them to effectively inhibit the activity of proteins and enzymes critical for cancer cell survival.

It refers to the segment of the pharmaceutical industry dedicated to developing and commercializing drugs specifically designed to target and inhibit the growth of cancer cells through small molecules. These therapies work by interfering with specific molecules involved in the growth, progression, and spread of cancer, thereby offering more precise and targeted treatment options compared to traditional chemotherapy.

According to the FDA, the half life of monoclonal antibodies like cetuximab (3.1-7.8 days) is much longer than those of small-molecule agents like gefitinib (48 hours).

Market Dynamics:

Driver:

Increasing incidence of cancer

With cancer rates on the rise across various demographics and geographies, there is a growing demand for effective treatment options. Small molecule targeted therapies offer promising avenues for cancer treatment by specifically targeting molecular alterations in cancer cells, thereby inhibiting their growth or inducing cell death with minimal harm to healthy cells. Additionally, as traditional treatments like chemotherapy often come with debilitating side effects, the demand for more targeted and less toxic therapies is increasing.

Restraint:

High development costs

Developing small molecule drugs tailored to target specific cancer cells involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. The intricate process of identifying suitable molecular targets, designing compounds, optimizing their efficacy, and ensuring their safety demands substantial financial investments. However, the rigorous regulatory requirements and lengthy approval timelines further escalate the overall development costs. For smaller biotechnology companies or startups with limited financial resources, these high costs present a considerable barrier to entry into the market.

Opportunity:

Technological advancements

Cutting-edge technologies such as high-throughput screening, molecular modeling, and computational chemistry enable the identification and design of small molecules with enhanced specificity and efficacy against cancer targets. Advances in analytical techniques facilitate the precise characterization of drug candidates, optimizing their pharmacokinetic and pharmacodynamic properties. Moreover, innovations in drug delivery systems, including nanotechnology and targeted drug delivery, enhance the therapeutic index of small molecule drugs by improving their tumor penetration and reducing off-target effects.

Threat:

Limited biomarkers

Biomarkers, which are measurable indicators of biological processes or responses to treatment, play a crucial role in identifying suitable patients for targeted therapies. The availability of biomarkers specific to certain types of cancer or targeted therapies is often limited. This limitation hampers the precise selection of patients who would benefit most from small molecule targeted therapies, leading to suboptimal treatment outcomes and potentially limiting market growth. Therefore, the lack of biomarkers limits the efficacy of targeted cancer medicines and also prevents market growth by reducing the number of patients that are eligible for these treatments.

Covid-19 Impact:

Disruptions in healthcare services and resources diverted attention and resources away from cancer treatment, leading to delays in diagnosis and initiation of therapy. Clinical trials for new small molecule targeted therapies faced interruptions or postponements, hindering the development and approval of new drugs. Supply chain disruptions and restrictions on movement further affected the manufacturing and distribution of existing therapies, causing shortages and delays in treatment access for patients. However, financial strains on healthcare systems and patients also impacted the affordability and utilization of these therapies.

The tyrosine kinase inhibitors segment is expected to be the largest during the forecast period

Due to their unique mechanism of action and effectiveness in treating various types of cancers. These inhibitors target specific tyrosine kinases, which are enzymes that play a crucial role in the signaling pathways involved in cancer cell growth and proliferation, Tyrosine Kinase Inhibitors segment is expected to hold the largest share during the projection period. Their precision targeting minimizes damage to healthy cells, leading to fewer adverse effects compared to traditional chemotherapy. Additionally, the development of novel TKIs with improved efficacy and reduced toxicity profiles has expanded treatment options for patients with different types of cancers, further driving market growth.

The melanoma segment is expected to have the highest CAGR during the forecast period

Melanoma segment is estimated to have the considerable growth over the forecast period. Melanoma, a type of skin cancer, has seen a substantial rise in incidence globally, driving the demand for effective treatments. Small molecule targeted therapies offer precision in combating melanoma by specifically targeting molecules involved in cancer growth and progression, resulting in enhanced efficacy and reduced side effects compared to traditional treatments. Additionally, advancements in research have led to the development of novel small molecule drugs tailored to target specific genetic mutations and pathways implicated in melanoma, expanding the therapeutic options available to patients. These elements are enhancing the segmental growth.

Region with largest share:

Because treatments for cancer are increasingly being customized to a patient's unique molecular profile, a phenomenon recognized as personalized medicine, the Asia Pacific region is expected to hold the largest share of the market during the projected period. Targeting specific small molecules in cancer patients may allow for more individualized and accurate treatment plans that take into account the particulars of their individual cases. As genome sequencing technology develops, it becomes simpler to find uncommon genetic anomalies and biomarkers connected to certain cancers. Furthermore, pharmaceutical companies can create highly targeted medications that are linked to certain genetic profiles due to the wealth of genetic data available in the area, improving treatment efficacy and precision.

Region with highest CAGR:

As healthcare providers become more knowledgeable about the benefits and effectiveness of targeted therapy in cancer treatment, they are more likely to recommend it to their patients, Asia Pacific region is estimated to witness profitable growth throughout the extrapolated period. This awareness leads to greater adoption of small molecule targeted therapies, which are designed to specifically target cancer cells while minimizing damage to healthy cells. Additionally, as healthcare providers in the region stay updated on the latest advancements and clinical evidence supporting targeted therapies, they become better equipped to identify suitable patients for these treatments and tailor therapy regimens to individual needs.

Key players in the market

Some of the key players in Small Molecule Targeted Cancer Therapy market include Abbott Laboratories, Amgen, AstraZeneca, Bayer HealthCare AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cytokinetics Inc, Genentech, GlaxoSmithKline plc, Hospira Inc and Novartis.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In February 2024, Erasca, Inc., a precision oncology company, has entered into clinical trial collaboration and supply agreements with pharmaceutical giant Novartis to advance the development of a new cancer treatment.

Types Covered:

  • Tyrosine Kinase Inhibitors
  • Small Molecule Drug Conjugates
  • Other Types

Applications Covered:

  • Breast Cancer
  • Multiple Myeloma
  • Melanoma
  • Lymphoma
  • Prostate Cancer
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Small Molecule Targeted Cancer Therapy Market, By Type

  • 5.1 Introduction
  • 5.2 Tyrosine Kinase Inhibitors
  • 5.3 Small Molecule Drug Conjugates
  • 5.4 Other Types

6 Global Small Molecule Targeted Cancer Therapy Market, By Application

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Multiple Myeloma
  • 6.4 Melanoma
  • 6.5 Lymphoma
  • 6.6 Prostate Cancer
  • 6.7 Other Applications

7 Global Small Molecule Targeted Cancer Therapy Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abbott Laboratories
  • 9.2 Amgen
  • 9.3 AstraZeneca
  • 9.4 Bayer HealthCare AG
  • 9.5 Boehringer Ingelheim GmbH
  • 9.6 Bristol-Myers Squibb
  • 9.7 Cytokinetics Inc
  • 9.8 Genentech
  • 9.9 GlaxoSmithKline plc
  • 9.10 Hospira Inc
  • 9.11 Novartis